Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection
Blood tests detecting early cancer signatures years before symptoms could enable screening for breast and prostate cancer before they become clinically apparent.
Published in Cell Genomics, this study demonstrates that genome-wide cell-free DNA methylation profiling can detect early cancer-associated signatures years before clinical diagnosis of breast and prostate cancer. The 491-sample cohort with up to 9-year pre-diagnosis lead time represents a landmark advance in non-invasive pre-clinical cancer detection.
What the study was
- Study design
- Prospective cohort / Genome-wide methylation profiling
- Population
- Pre-diagnosis breast and prostate cancer cohort, 491 plasma samples
- Sample size
- 491
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Cell genomics
Why it surfaced
Landmark cfDNA methylation study with 9-year pre-diagnosis detection window in major cancers; Cell Genomics publication, 491 pre-diagnosis plasma samples, directly advances liquid biopsy field.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.